Beumer H M
Military Hospital, Dr. A. Mathijsen, Utrecht, The Netherlands.
Int J Clin Pharmacol Ther Toxicol. 1989 Jan;27(1):30-3.
Sixty patients with lower respiratory tract infections, mainly acute bronchitis were treated for 14 days with either cefixime 200 mg twice daily (plus placebo once daily) or amoxicillin/clavulanic acid 500 mg/125 mg thrice daily in a double-blind manner. The sputum cultures indicated that all isolated pathogens (notably Hemophilus species, S. pneumoniae and B. catarrhalis, including the beta-lactamase producing species) were sensitive to cefixime, with the exception of Pseudomonas species. The bacteriological eradication rates were 54% and 52% for cefixime and amoxicillin/clavulanic acid, respectively. The positive clinical response (cured or improved) was 71% for the cefixime treated group and 74% in the amoxicillin/clavulanic acid group. There were no side effects and no significant adverse laboratory changes in both groups. The results indicate that cefixime twice daily is comparable in safety and efficacy with amoxicillin/clavulanic acid, thrice daily in acute bronchitis.
60例主要患有急性支气管炎的下呼吸道感染患者，以双盲方式接受为期14天的治疗，其中一组每日两次服用200毫克头孢克肟（加每日一次服用安慰剂），另一组每日三次服用500毫克/125毫克阿莫西林/克拉维酸。痰培养表明，所有分离出的病原体（尤其是嗜血杆菌属、肺炎链球菌和卡他莫拉菌，包括产β-内酰胺酶的菌种）对头孢克肟敏感，但铜绿假单胞菌属除外。头孢克肟和阿莫西林/克拉维酸的细菌学根除率分别为54%和52%。头孢克肟治疗组的临床阳性反应（治愈或改善）为71%，阿莫西林/克拉维酸组为74%。两组均无副作用，实验室检查也无显著不良变化。结果表明，在急性支气管炎治疗中，每日两次服用头孢克肟在安全性和疗效方面与每日三次服用阿莫西林/克拉维酸相当。
